- Home
- ESTC vs MDGL Comparison
ESTC vs MDGL Comparison
Compare ESTC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTC | MDGL |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 12.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESTC | MDGL |
|---|---|---|
| Price | $76.81 | $607.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 14 |
| Target Price | $107.38 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 1.8M | 298.4K |
| Earning Date | 11-20-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,609,284,000.00 | $740,640,000.00 |
| Revenue This Year | $18.25 | $435.63 |
| Revenue Next Year | $13.63 | $52.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 16.98 | ★ 864.21 |
| 52 Week Low | $68.10 | $265.00 |
| 52 Week High | $118.84 | $609.98 |
Technical Indicators
Market Signals| Indicator | ESTC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.94 | 65.63 |
| Support Level | $75.81 | $535.33 |
| Resistance Level | $78.78 | $609.98 |
| Average True Range (ATR) | 2.46 | 20.31 |
| MACD | 0.68 | 0.28 |
| Stochastic Oscillator | 52.48 | 84.71 |
Price Performance
Historical ComparisonAbout ESTC Elastic N.V.
Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.